
Hoth Therapeutics (HOTH) Stock Forecast & Price Target
Hoth Therapeutics (HOTH) Analyst Ratings
Bulls say
Hoth Therapeutics Inc. is advancing its clinical-stage pipeline, which encompasses multiple promising therapies targeting unmet medical needs, particularly in oncology and metabolic diseases, through its dual-track strategy. The company's recent data indicates that over 65% of participants in their studies experienced significant reductions in pain and pruritus, demonstrating the potential effectiveness of their treatments. Additionally, Hoth's disciplined expense management in their recent financial results highlights the company's commitment to fiscal responsibility while driving the development of its lead asset, HT-001.
Bears say
Hoth Therapeutics Inc reported no revenues for the second quarter of 2025, while total operating expenses decreased to $2.2 million from $3.4 million in the prior quarter. The company recorded a net loss of $2.2 million, equivalent to $(0.17) per share, highlighting ongoing financial challenges. The lack of revenue generation, combined with continuing operating expenses and consistent net losses, contributes to a negative outlook for the company’s stock.
This aggregate rating is based on analysts' research of Hoth Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Hoth Therapeutics (HOTH) Analyst Forecast & Price Prediction
Start investing in Hoth Therapeutics (HOTH)
Order type
Buy in
Order amount
Est. shares
0 shares